Potential Synergies With T-Cell Engagers
Joshua K. Sabari, MD, discusses the potential treatment synergies expected from combining MK-6070, a trispecific T-cell engager, with ifinatamab deruxtecan, noting that specific patient and disease factors (eg, tumor expression profiles and previous treatment responses) could influence the decision to pursue dual T-cell engager therapy in early clinical development.
Video content above is prompted by the following:
In your opinion, what treatment synergies might you expect from a combination of MK-6070, the trispecific T-cell engager, and ifinatamab deruxtecan?
• At this stage in early clinical development, which patient and/or disease factors might persuade you to consider dual T-cell engager therapy?
Recent Videos
Related Content
